{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:14:29Z","timestamp":1760552069796,"version":"build-2065373602"},"reference-count":35,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>Background: Intravenous (IV) vancomycin area under the curve (AUC)-based dosing is used uniformly for Gram-positive organisms in non-teaching community hospitals. However, evidence for using vancomycin AUC-based dosing for non-methicillin-resistant Staphylococcus aureus (non-MRSA) and less serious infections is limited in the literature. A gap in the literature also exists with respect to comparisons between the outcomes that can be derived using the regimens suggested by Bayesian programs and target doses of the AUC of 400\u2013499 and 500\u2013600. Methods: A retrospective review of all patients hospitalized in a non-teaching community hospital who used AUC-based vancomycin was performed over a 1-year period. Results: Only 17.6% of the included patients had confirmed MRSA. The values for the overall early response rate, 30-day all-cause mortality, and rate of acute kidney injury (AKI) were 50.3%, 11.3%, and 3.8%, respectively, in this population. In regression analysis, compared to non-MRSA infections, a significantly higher rate of early response was seen in patients with MRSA (unadjusted OR = 2.68, 95% CI [1.06\u20136.76] p = 0.04). Patients in the AUC 400\u2013499 group had a non-significant higher incidence of 30 d mortality and new AKI compared to patients in the AUC 500\u2013600 group. In our Kaplan\u2013Meier survival analysis, there was no statistically significant difference between the comparison groups. Conclusions: Early response was lower in patients with non-MRSA compared to patients with MRSA despite achieving the AUC target. There was no apparent difference in clinical outcomes between the higher and lower AUC groups. Further large-scale research is needed to confirm these findings.<\/jats:p>","DOI":"10.3390\/pharmacy12010015","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T04:16:56Z","timestamp":1705465016000},"page":"15","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vancomycin AUC-Based Dosing Practices in a Non-Teaching Community Hospital and Associated Outcomes: A One-Year Survey of Uniform Targets for Infections with or without MRSA"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-5729","authenticated-orcid":false,"given":"Iftekharul","family":"Islam","sequence":"first","affiliation":[{"name":"Department of Pharmacy, MedStar Montgomery Medical Center, Olney, MD 20832, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of health-system pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health-Syst. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s13318-017-0456-4","article-title":"Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice","volume":"43","author":"Elbarbry","year":"2018","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/phar.2722","article-title":"Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis","volume":"42","author":"Abdelmessih","year":"2022","journal-title":"Pharmacotherapy"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Matsumoto, K., Oda, K., Shoji, K., Hanai, Y., Takahashi, Y., Fujii, S., Hamada, Y., Kimura, T., Mayumi, T., and Ueda, T. (2022). Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14030489"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"American Society of Health-System Pharmacists (2009). Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am. J. Health-Syst. Pharm., 66, 82\u201398.","DOI":"10.2146\/ajhp080434"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious gram-positive infections","volume":"11","author":"Menichetti","year":"2005","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1186\/s12879-016-2080-3","article-title":"Frequency of empiric antibiotic de-escalation in an acute care hospital with an established Antimicrobial Stewardship Program","volume":"16","author":"Liu","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ccm.2011.05.009","article-title":"De-escalation therapy: Is it valuable for the management of ventilator-associated pneumonia?","volume":"32","author":"Niederman","year":"2011","journal-title":"Clin. Chest Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: A summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of health-system pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ijantimicag.2018.12.014","article-title":"The dosing and monitoring of vancomycin: What is the best way forward?","volume":"53","author":"Drennan","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/ajhp\/zxaa128","article-title":"Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and \u03b2-lactam antibiotics to maximize effectiveness and minimize toxicity","volume":"77","author":"Cusumano","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Katip, W., and Oberdorfer, P. (2021). A monocentric retrospective study of AUC\/MIC ratio of vancomycin associated with clinical outcomes and nephrotoxicity in patients with Enterococcal infections. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091378"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e4560","DOI":"10.1093\/cid\/ciaa1039","article-title":"Vancomycin area under the curve to predict timely clinical response in the treatment of methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections","volume":"73","author":"Alosaimy","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Tochikura, N., Matsumoto, C., Iwabuchi, S., Aso, H., Fukushima, S., Ootsuka, S., Ooba, N., Ishihara, M., Nakajima, H., and Umemura, H. (2023). Pharmacokinetic\/pharmacodynamic analysis of vancomycin in patients with Enterococcus faecium bacteraemia: A retrospective cohort study. Eur. J. Hosp. Pharm.","DOI":"10.1136\/ejhpharm-2022-003672"},{"key":"ref_15","unstructured":"InsightRX Nova (2023, September 01). InsightRX. Available online: https:\/\/www.insight-rx.com."},{"key":"ref_16","unstructured":"(2023, September 01). BD PhoenixTM Automated Identification and Susceptibility Testing System. Available online: www.bd.com."},{"key":"ref_17","unstructured":"(2023, September 01). Centers for Disease Control and Prevention. Emerging Infections Program, Healthcare-Associated Infections\u2014Community Interface Surveillance Report, Invasive Staphylococcus aureus, 2020, Available online: https:\/\/www.cdc.gov\/hai\/eip\/pdf\/2020-MRSA-Report-508.pdf."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ueda, T., Takesue, Y., Nakajima, K., Ichiki, K., Ishikawa, K., Yamada, K., Tsuchida, T., Otani, N., Takahashi, Y., and Ishihara, M. (2022). Validation of vancomycin area under the concentration\u2014Time curve estimation by the Bayesian approach using one-point samples for predicting clinical outcomes in patients with methicillin-resistant Staphylococcus aureus infections. Antibiotics, 11.","DOI":"10.3390\/antibiotics11010096"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1128\/AAC.05609-11","article-title":"Vancomycin AUC24\/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization","volume":"56","author":"Brown","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sasano, H., and Hanada, K. (2023). Assessing Clinical Outcomes of Vancomycin Treatment in Adult Patients with Vancomycin-Susceptible Enterococcus faecium Bacteremia. Antibiotics, 12.","DOI":"10.3390\/antibiotics12111577"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40780-019-0138-2","article-title":"Association between vancomycin pharmacokinetic\/pharmacodynamic parameters, patient characteristics, and mortality in patients with bacteremia caused by vancomycin-susceptible Enterococcus faecium: A single-center retrospective study","volume":"5","author":"Nakakura","year":"2019","journal-title":"J. Pharm. Health Care Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e01602-17","DOI":"10.1128\/AAC.01602-17","article-title":"Pharmacokinetic\/Pharmacodynamic Determinants of Vancomycin Efficacy in Enterococcal Bacteremia","volume":"62","author":"Jumah","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/1471-2334-11-279","article-title":"Comparative effectiveness of Nafcillin or CEFAZOLIN versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia","volume":"11","author":"Schweizer","year":"2011","journal-title":"BMC Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Alsowaida, Y.S., Benitez, G., Bin Saleh, K., Almangour, T.A., Shehadeh, F., and Mylonakis, E. (2022). Effectiveness and Safety of Ceftriaxone Compared to Standard of Care for Treatment of Bloodstream Infections Due to Methicil-lin-Susceptible Staphylococcus aureus: A Systematic Review and Meta-Analysis. Antibiotics, 11.","DOI":"10.3390\/antibiotics11030375"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000513742","article-title":"Nephrotoxicity from vancomycin combined with Piperacillin-Tazobactam: A comprehensive review","volume":"52","author":"Blair","year":"2021","journal-title":"Am. J. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/87551225221101736","article-title":"Evaluating the Safety of Trough Versus Area Under the Curve (AUC)-Based Dosing Method of Vancomycin With Concomitant Piperacillin-Tazobactam","volume":"38","author":"Karas","year":"2022","journal-title":"J. Pharm. Technol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jgar.2021.07.018","article-title":"Candidates for area under the concentration-time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients","volume":"27","author":"Hashimoto","year":"2021","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Chiu, C.Y., and Sarwal, A. (2023). Evaluating the Nephrotoxicity of Area-under-the-Curve-Based Dosing of Vancomycin with Concomitant Antipseudomonal Beta-Lactam Antibiotics: A Systematic Review and Meta-Analysis. Medicina, 59.","DOI":"10.3390\/medicina59040691"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1111\/bcp.15429","article-title":"Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis","volume":"88","author":"Kim","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000343162","article-title":"Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillinresistant Staphylococcus aureus pneumonia","volume":"58","author":"Suzuki","year":"2012","journal-title":"Chemotherapy"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: A meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin. Infect Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1128\/AAC.03970-14","article-title":"Association between vancomycin day 1 exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis","volume":"59","author":"Casapao","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/cid\/ciu398","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: How much is enough?","volume":"59","author":"Lodise","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_35","unstructured":"Sergeant, E.S.G. (2018). Epitools Epidemiological Calculators. Ausvet, Available online: http:\/\/epitools.ausvet.com.au."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/1\/15\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:48:33Z","timestamp":1760104113000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/12\/1\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["pharmacy12010015"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy12010015","relation":{},"ISSN":["2226-4787"],"issn-type":[{"type":"electronic","value":"2226-4787"}],"subject":[],"published":{"date-parts":[[2024,1,17]]}}}